1552-4930/asset/olbannerleft.gif?v=1&s=cf6fcbfdc8ffa722551b71f8be0977b5b04db6ee)
1552-4930/asset/olbannerright.gif?v=1&s=6d0ba4e64946e5d9d4ebba4b8395a68bf324cd0b)
Original Article
You have full text access to this OnlineOpen article
Development of Herceptin resistance in breast cancer cells
Article first published online: 29 DEC 2003
DOI: 10.1002/cyto.a.10095
Copyright © 2004 Wiley-Liss, Inc.
1552-4930/asset/cover.gif?v=1&s=3df33f34517aaa739d7876df137e2ab92c5f82e7 "Cytometry Part A")
Additional Information
How to Cite
Kute, T., Lack, C. M., Willingham, M., Bishwokama, B., Williams, H., Barrett, K., Mitchell, T. and Vaughn, J. P. (2004), Development of Herceptin resistance in breast cancer cells. Cytometry, 57A: 86–93. doi: 10.1002/cyto.a.10095
Publication History
- Issue published online: 22 JAN 2004
- Article first published online: 29 DEC 2003
- Manuscript Accepted: 13 AUG 2003
- Manuscript Revised: 9 JUL 2003
- Manuscript Received: 19 DEC 2002
Funded by
- Wake Forest University Cancer Center Push Grant
- National Cancer Institute. Grant Number: RO1-CA 83953
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , , , , Chemotherapy targeting by DNA capture in viral protein particles, Nanomedicine, 2012, 7, 3, 335
- 2
- 3, , Omics and therapy – A basis for precision medicine, Molecular Oncology, 2012, 6, 2, 128
- 4, , , , , , , , , , A Mechanistic Study of Tumor-Targeted Corrole Toxicity, Molecular Pharmaceutics, 2011, 8, 6, 2233
- 5, One target, different effects: a comparison of distinct therapeutic antibodies against the same targets, Experimental and Molecular Medicine, 2011, 43, 10, 539
- 6
- 7, , , , The challenge of developing robust drugs to overcome resistance, Drug Discovery Today, 2011,
- 8
- 9, , , , , , , , , , , , In vivo activity of novel anti-ErbB2 antibody chA21 alone and with Paclitaxel or Trastuzumab in breast and ovarian cancer xenograft models, Cancer Immunology, Immunotherapy, 2010, 60, 3, 339
- 10, , , Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors, Anti-Cancer Drugs, 2010, 21, 2, 151
- 11, , , , , A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth, Biochemical and Biophysical Research Communications, 2009, 384, 3, 329
- 12, , , , , , , Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing, Cancer Immunology, Immunotherapy, 2009, 58, 11, 1887
- 13, , , , , , , , , , , , Immunotherapy for Osteosarcoma: Genetic Modification of T cells Overcomes Low Levels of Tumor Antigen Expression, Molecular Therapy, 2009, 17, 10, 1779
- 14, , , Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells, International Journal of Cancer, 2009, 124, 4Direct Link:
- 15
- 16, , , , , , , , , , Relationship between p53 and p27 expression following HER2 signaling, The Breast, 2007, 16, 6, 597
- 17
- 18, , , , , Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer, Nature Clinical Practice Oncology, 2006, 3, 5, 269
- 19, , , Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors, Breast Cancer Research and Treatment, 2005, 91, 2, 187
- 20, , , , , Molecular Modeling of Nearly Full-Length ErbB2 Receptor, Biophysical Journal, 2005, 88, 2, 1354